Clinical Trials · NCT07314684
GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM
- Phase
- Phase 4
- Recruitment status
- Recruiting
- Sponsor
- Federico II University
- Enrollment
- 80
- Start date
- Sep 2025
- Locations
- 2 sites, Italy
- Primary endpoint
- To evaluate the effects of semaglutide in addition to standard therapy on inflammatory biomarkers compared with standard therapy alone in T2DM patients without ASCVD or severe TOD but with SCORE2-Diabetes ≥10%.